Combinations of immunotherapy with anti-angiogenic agents for the treatment of recurrent ovarian cancer
| Trial name/identification | Phase | Treatment(s) | Disease setting | Sample size | Follow-up (median months) | Objective response rate (%) | Progression-free survival (median months) | Overall survival (median months) |
| Lee et al. 201754 | I | Durvalumab+ cediranib | Recurrent platinum-sensitive/resistant ovarian cancer | 26 | Not reported | 50% | Not reported | Not reported |
| Liu et al. 201955 | II | Nivolumab+ bevacizumab | Relapsed platinum-sensitive/resistant ovarian cancer | 38 | Not reported | 28.9% | 8.1 | Not reported |
| LEAP 005 (González-Martín et al. 2020)56 | II | Lenvatinib+ pembrolizumab | Previously treated ovarian cancer | 31 | 7.8 | 32% | 4.4 | Not reported |
| EORTC-1508 (Banerjee et al. 2021)57 | II | Atezolizumab+ bevacizumab (±acetylsalicylic acid) vs bevacizumab vs atezolizumab vs atezolizumab+ acetylsalicylic acid | Recurrent platinum-resistant ovarian cancer | 122 | Not reported | 15.2% atezolizumab+ bevacizumab + acetylsalicylic acid 19.4% atezolizumab+ bevacizumab 9.7% bevacizumab | 4.0 atezolizumab+ bevacizumab + acetylsalicylic acid 4.1 atezolizumab+ bevacizumab 2.3 bevacizumab 2.1 atezolizumab 2.2 atezolizumab+ acetylsalicylic acid | 11.6 atezolizumab+ bevacizumab + acetylsalicylic acid 12.1 atezolizumab+ bevacizumab 10.4 bevacizumab |